Overview

Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC

Status:
Active, not recruiting

Trial end date:
2022-01-31

Target enrollment:

Participant gender:

Summary

Safety and Efficacy Study of Radioembolization with Yttrium-90 Microspheres in Combination with Durvalumab in Locally Advanced Hepatocellular Carcinoma

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Seoul National University Hospital

Treatments:

Antibodies, Monoclonal
Durvalumab